Taken together, these findings underscore the multifaceted nature of treatment resistance—spanning histologic transformation, EMT, and intercellular communication—and highlight the need for innovative, multi-pronged strategies to improve outcomes for patients with EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.